EFFICACY OF TEDUGLUTIDE IN PATIENTS WITH SHORT BOWEL SYNDROME ON HOME PARENTERAL NUTRITION: A REAL LIFE STUDY

Teduglutide is a GLP-2 analogue indicated for treatment of adults with short bowel syndrome (SBS) reducing parenteral support (PS) requirements. The present report aims to describe the effects of teduglutide in 3 patients on HPN for SBS clinically heterogeneous and with variable length of parenteral support from 4 to 25 years. Between 2017 and 2018, 3 patients with short bowel syndrome in home parenteral nutrition, clinically stable for at least 6 months, receveid daily subcutaneous injection of 0,05 mg/kg/day teduglutide. All patients had undergone, before treatment, a colonoscopy/ileoscopy for the purpose of polyp surveillance and a abdomen ultrasound which was normal. A history of cancer with fewer than 5 years was excluded. A clinically significant reduction from baseline in weekly parenteral support volume and calories was observed in patients, respectively ranging from about -31,8% and -31,1% at 3 months, -49,1% and -48,2% at 12 months. This was associated with an increase in parenteral nutrition-free days, ranging from about 2,3 days/week in 3 months and 4 days/week in 12 months. Stool frequency and volume decreased and consistency increased. Nutritional status evaluation revealed stability in body weight and food intake altrought parenteral support reduction. No serious adverse events were observed during treatment. Patients reported an improvement of quality of life, assessed using SF-36. This real life study demonstrated safety and efficacy of teduglutide suggesting reduction in parenteral support is associated with improvement of quality of life.